Lisata Therapeutics, Inc. (LSTA)
1.89
+0.03
(+1.61%)
USD |
NASDAQ |
Sep 09, 14:38
Lisata Therapeutics Enterprise Value : 6.264M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 6.264M |
| September 04, 2026 | 4.349M |
| September 03, 2026 | 4.258M |
| September 02, 2026 | 3.620M |
| September 01, 2026 | 3.620M |
| August 31, 2026 | 2.890M |
| August 28, 2026 | 4.714M |
| August 27, 2026 | 5.900M |
| August 26, 2026 | 5.808M |
| August 25, 2026 | 5.170M |
| August 24, 2026 | 5.352M |
| August 21, 2026 | 3.437M |
| August 20, 2026 | -0.4837M |
| August 19, 2026 | -0.4837M |
| August 18, 2026 | -0.2102M |
| August 17, 2026 | -0.8485M |
| August 14, 2026 | -0.7573M |
| August 13, 2026 | -0.3925M |
| August 12, 2026 | 0.0634M |
| August 11, 2026 | 0.337M |
| August 10, 2026 | -0.7573M |
| August 07, 2026 | -1.031M |
| August 06, 2026 | -0.9397M |
| August 05, 2026 | -0.4837M |
| August 04, 2026 | -0.3013M |
| Date | Value |
|---|---|
| August 03, 2026 | -1.213M |
| July 31, 2026 | -1.669M |
| July 30, 2026 | -1.304M |
| July 29, 2026 | -0.7573M |
| July 28, 2026 | -0.119M |
| July 27, 2026 | 2.434M |
| July 24, 2026 | 4.532M |
| July 23, 2026 | 8.635M |
| July 22, 2026 | 9.365M |
| July 21, 2026 | 9.730M |
| July 20, 2026 | 21.45M |
| July 17, 2026 | 22.09M |
| July 16, 2026 | 21.22M |
| July 15, 2026 | 23.50M |
| July 14, 2026 | 23.13M |
| July 13, 2026 | 23.04M |
| July 10, 2026 | 19.12M |
| July 09, 2026 | 18.80M |
| July 08, 2026 | 18.58M |
| July 07, 2026 | 19.12M |
| July 06, 2026 | 19.85M |
| July 02, 2026 | 19.67M |
| July 01, 2026 | 19.94M |
| June 30, 2026 | 20.31M |
| June 29, 2026 | 17.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.929M |
| Total Expenses (Quarterly) | 2.929M |
| EPS Diluted (Quarterly) | -0.3217 |
| Earnings Yield | -86.81% |
| Normalized Earnings Yield | -86.81 |